Evaluation of Twenty-One Human Adenovirus Types and One Infectivity-Enhanced Adenovirus for the Treatment of Malignant Melanoma  Dennis Hoffmann, Wibke.

Slides:



Advertisements
Similar presentations
Molecular Therapy - Oncolytics
Advertisements

Jane L. Armstrong, David S. Hill, Christopher S
Amanda M. Nelson, Kathryn L. Gilliland, Zhaoyuan Cong, Diane M
A Signal Transduction Pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its Correlation with Progression in Human Melanoma  Xuan Qu, Liangliang Shen,
Therapeutic Improvement of a Stroma-Targeted CRAd by Incorporating Motives Responsive to the Melanoma Microenvironment  Diego L. Viale, Eduardo G. Cafferata,
Molecular Therapy - Oncolytics
Yongping Shao, Kaitlyn Le, Hanyin Cheng, Andrew E. Aplin 
Antigen-Specific CD8 T Cells Can Eliminate Antigen-Bearing Keratinocytes with Clonogenic Potential via an IFN-γ-Dependent Mechanism  Rachel L. De Kluyver,
Christian Posch, Brian D
Volume 8, Issue 3, Pages (September 2003)
Cyclooxygenase-2 Overexpression in Human Basal Cell Carcinoma Cell Line Increases Antiapoptosis, Angiogenesis, and Tumorigenesis  Jeng-Wei Tjiu, Yi-Hua.
Effects of Betulinic Acid Alone and in Combination with Irradiation in Human Melanoma Cells  Edgar Selzer, Emilio Pimentel, Volker Wacheck, Werner Schlegel,
Efficient TRAIL-R1/DR4-Mediated Apoptosis in Melanoma Cells by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)  Bahtier M. Kurbanov, Christoph.
Regulation of Human Melanoma Growth and Metastasis by AGE–AGE Receptor Interactions  Riichiro Abe, Tadamichi Shimizu, Hiroshi Sugawara, Hirokazu Watanabe,
IL-13-Stimulated Human Keratinocytes Preferentially Attract CD4+CCR4+ T cells: Possible Role in Atopic Dermatitis  Rahul Purwar, Thomas Werfel, Miriam.
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
Chemovirotherapy of Malignant Melanoma with a Targeted and Armed Oncolytic Measles Virus  Johanna K. Kaufmann, Sascha Bossow, Christian Grossardt, Stefanie.
Valentina Manfé, Edyta Biskup, Peter Johansen, Maria R
EGFR Regulates the Expression of Keratinocyte-Derived Granulocyte/Macrophage Colony-Stimulating Factor In Vitro and In Vivo  Francesca Mascia, Christophe.
Diagnostic and Therapeutic Evaluation of an Anti-Langerhans Cell Histiocytosis Monoclonal Antibody (NA1/34) in a New Xenograft Model  Samuel Murray, Jenny.
Molecular Therapy - Oncolytics
Volume 10, Issue 5, Pages (November 2004)
17β-estradiol, Progesterone, and Dihydrotestosterone Suppress the Growth of Human Melanoma by Inhibiting Interleukin-8 Production  Naoko Kanda, Shinichi.
The Hematopoietic Stem Cell Regulatory Gene Latexin Has Tumor-Suppressive Properties in Malignant Melanoma  Viswanathan Muthusamy, Sanjay Premi, Cara.
Decreased Growth Inhibitory Responses of Squamous Carcinoma Cells to Interferon-γ Involve Failure to Recruit cki Proteins into cdk2 Complexes  Beth L.
Human Papilloma Virus E6 and E7 Proteins Support DNA Replication of Adenoviruses Deleted for the E1A and E1B Genes  Dirk S. Steinwaerder, Cheryl A. Carlson,
T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
MiTF Regulates Cellular Response to Reactive Oxygen Species through Transcriptional Regulation of APE-1/Ref-1  Feng Liu, Yan Fu, Frank L. Meyskens  Journal.
Alexander J. Lakhter, Ravi P. Sahu, Yang Sun, William K
Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment  Elin S. Gray, Anna L. Reid, Samantha Bowyer, Leslie.
New generation adenoviral vectors improve gene transfer by coxsackie and adenoviral receptor-independent cell entry  Paul N. Reynolds, David T. Curiel 
An Actin-Binding Protein Espin Is a Growth Regulator for Melanoma
Volume 103, Issue 3, Pages (October 2000)
Dominique Maciejewski-Lenoir, Jeremy G
Einar K. Rofstad, Bjørn A. Graff  Journal of Investigative Dermatology 
Volume 24, Issue 9, Pages (September 2016)
SPARC Endogenous Level, rather than Fibroblast-Produced SPARC or Stroma Reorganization Induced by SPARC, Is Responsible for Melanoma Cell Growth  Federico.
Sri Rajalakshmi Rudrabhatla, Christie L. Mahaffey, Mark E. Mummert 
Mycobacterium Tuberculosis-Induced Cell Death of Primary Human Monocytes and Macrophages Is Not Significantly Modulated by Tumor Necrosis Factor-Targeted.
Volume 7, Issue 1, Pages (January 2003)
Christiane Thallinger, Markus F
Yabin Cheng, Guangdi Chen, Magdalena Martinka, Vincent Ho, Gang Li 
Volume 29, Issue 6, Pages (December 2008)
Molecular Therapy - Oncolytics
Volume 22, Issue 1, Pages (January 2014)
Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.
Michael D. Howell, Joanne E. Streib, Byung Eui Kim, Leighann J
Wound Healing in the α2β1 Integrin-Deficient Mouse: Altered Keratinocyte Biology and Dysregulated Matrix Metalloproteinase Expression  David G. Grenache,
Imiquimod Enhances the Systemic Immunity Attained by Local Cryosurgery Destruction of Melanoma Lesions  Pedro Redondo, Julio del Olmo, Ascensión López-Diaz.
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
Regulation of the Melanoma Cell Adhesion Molecule Gene in Melanoma: Modulation of mRNA Synthesis by Cyclic Adenosine Monophosphate, Phorbol Ester, and.
Bim Expression Is Reduced in Human Cutaneous Melanomas
BMP-4 Upregulates Kit Expression in Mouse Melanoblasts prior to the Kit-Dependent Cycle of Melanogenesis  Tamihiro Kawakami, Satoko Kimura, Yoko Kawa,
Dysregulation of Lymphocyte Interleukin-12 Receptor Expression in Sézary Syndrome  Mohamed H. Zaki, Ryan B. Shane, Yuemei Geng, Louise C. Showe, Suzanne.
Volume 20, Issue 5, Pages (May 2012)
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
RhoC Promotes Human Melanoma Invasion in a PI3K/Akt-Dependent Pathway
Efficient In Vitro Transfection of Human Keratinocytes with an Adenovirus-Enhanced Receptor-Mediated System  Marcel Huber, Daniel Hohl  Journal of Investigative.
Oct-4: The Almighty POUripotent Regulator?
Serotonin Activates Human Monocytes and Prevents Apoptosis
Sangeet Lal, Corey Raffel  Molecular Therapy - Oncolytics 
Volume 6, Issue 3, Pages (September 2002)
Yunyuan Li, Edward E. Tredget, Abdi Ghaffari, Xiaoyue Lin, Ruhangiz T
Valerie Künzi, Patrick A
Volume 10, Issue 6, Pages (December 2004)
Molecular Therapy - Oncolytics
Jane L. Armstrong, David S. Hill, Christopher S
Molecular Therapy - Oncolytics
Yoshinori Aragane, Akira Maeda, Chang-Yi Cui, Tadashi Tezuka 
Volume 15, Issue 2, Pages (February 2007)
Presentation transcript:

Evaluation of Twenty-One Human Adenovirus Types and One Infectivity-Enhanced Adenovirus for the Treatment of Malignant Melanoma  Dennis Hoffmann, Wibke Bayer, Albert Heim, Anja Potthoff, Dirk M. Nettelbeck, Oliver Wildner  Journal of Investigative Dermatology  Volume 128, Issue 4, Pages 988-998 (April 2008) DOI: 10.1038/sj.jid.5701131 Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Immunohistochemical analysis of primary cutaneous malignant melanoma lesions. The diagnosis of malignant melanoma (MM) was confirmed by positive immunostaining for HMB45 in melanocytes (Gown et al., 1986). Since treatment efficacy of adenovirus critically depends on the expression on the primary cellular receptor, we stained for CAR and CD46. CAR is the functional cellular receptor of Ad5 (Bergelson et al., 1997; Tomko et al., 1997) and CD46, the cellular receptor for all species B (Gaggar et al., 2003; Segerman et al., 2003b; Sirena et al., 2004) and some species D adenoviruses (Wu et al., 2004; Lemckert et al., 2006). Three representative slides out of five patients with primary cutaneous melanoma are shown; original magnification × 400. Journal of Investigative Dermatology 2008 128, 988-998DOI: (10.1038/sj.jid.5701131) Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 2 Analysis of internalization of adenovirus types. (a) Monolayers of permanent melanoma cell lines (A375, Sk-Mel2, 888) and of short-term cultures of malignant melanoma cells (pMel-A1, pMel-L, pMel-M, pMel-P and pMel-S) were infected for 1hour with equal amounts of 3H-thymidine-labeled adenovirus types. To remove unbound or attached but not internalized VPs, cells were incubated at 37°C for 30minutes with trypsin-EDTA and the number of internalized virions per cell was determined by scintillation counting. Virus internalization of the analyzed permanent melanoma cell lines and of the five short-term cultures of melanoma cells were grouped and presented as mean±SD from three independent experiments. A549 cells served as a control for CAR+ cells. The currently known primary adenovirus cellular receptors are indicated. (b) To analyze the data shown in (a), we determined the ratio of adenovirus internalization efficiency in melanoma cells vs A549 cells. A ratio ≥1 suggests preferential infection of melanoma cells when compared to A549 cells. (c) Using flow cytometrical analysis, we determined the cell surface density of CAR, CD46, and CD80 on melanoma cells. The mean fluorescence intensity correlates directly with the cell surface density of the receptors, which can mediate attachment of some tested adenovirus types. Journal of Investigative Dermatology 2008 128, 988-998DOI: (10.1038/sj.jid.5701131) Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 3 Vector design. (a) Design of double heterologous promoter-controlled oncolytic Ad5-based vectors. To target viral replication and lysis to melanoma cells, the E1 and E4 gene regions, which are essential for adenovirus replication, were placed under the transcriptional control of indicated heterologous promoters. In addition, the vectors encompass a 24-bp deletion in the E1A CR2 (E1Δ24) domain that is responsible for viral E1A binding to the retinoblastoma protein as described previously (Fueyo et al., 2000). We generated these oncolytic vectors as an Ad5/35 fiber chimera and its homologous counterpart with the native Ad5 fiber. (b) Design of measles virus fusogenic membrane proteins H and F (MV-H/F) encoding Ad5-based vectors with chimeric Ad5/35 or native Ad5 fiber. Journal of Investigative Dermatology 2008 128, 988-998DOI: (10.1038/sj.jid.5701131) Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 4 Analysis of combined drug effects. Permanent melanoma cell lines (A375 and Sk-Mel2) and short-term cultures of melanoma cells (pMel-L and pMel-S) were exposed in vitro for 36hours to DTIC alone or in combination with the replication-defective adenovirus vector Ad5/35.H/F encoding measles virus fusogenic membrane proteins H and F at a constant molar ratio. (a) Cytotoxicity was assessed by bioluminescence and dose–effect curves were generated. (b) To quantitate the interaction between the treatments, CI vs cytotoxicity plots were generated from the median-effect plots (Chou and Talalay, 1984). For these curves, CI<1 defines a synergistic interaction and CI>1 antagonistic drug effects. The straight line at the CI=1 represents the additive effects of both drugs. The CI values for the 50% effective dose (ED50) are indicated. Journal of Investigative Dermatology 2008 128, 988-998DOI: (10.1038/sj.jid.5701131) Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 5 Kaplan–Meier survival analysis. The short-term cell culture pMel-S, derived from a primary human cutaneous malignant melanoma, was used to establish a subcutaneous xenograft model in nude mice. The primary tumor as well as the derived short-term culture and the xenografts were negative for the functional receptor of Ad5, the CAR (data only partially shown). When xenografts reached a volume of ~200mm3, groups of 10 mice were treated on day 0 and day 2 with a replication-defective adenovirus encoding measles virus H and F (Ad5/35.H/F or Ad5.H/F) alone or in combination with DTIC, and/or a replication-restricted oncolytic adenovirus vector (Ad5/35Δ24.Ki·COX or Ad5Δ24Ki·COX). The vectors Ad5/35 and Ad5 differed only in the fiber. For clarity, the survival plots were separated into three graphs. Journal of Investigative Dermatology 2008 128, 988-998DOI: (10.1038/sj.jid.5701131) Copyright © 2008 The Society for Investigative Dermatology, Inc Terms and Conditions